The estimated Net Worth of Richard W Pascoe is at least $921 Tysiąc dollars as of 13 January 2023. Mr. Pascoe owns over 9,500 units of Seelos Therapeutics stock worth over $3,995 and over the last 9 years he sold SEEL stock worth over $0. In addition, he makes $917,292 as Director at Seelos Therapeutics.
Sign up
Mr. Pascoe SEEL stock SEC Form 4 insiders trading
Richard has made over 4 trades of the Seelos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 9,500 units of SEEL stock worth $51,680 on 13 January 2023.
The largest trade he's ever made was buying 10,000 units of Seelos Therapeutics stock on 18 August 2020 worth over $6,400. On average, Richard trades about 867 units every 29 days since 2015. As of 13 January 2023 he still owns at least 19,973 units of Seelos Therapeutics stock.
You can see the complete history of Mr. Pascoe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Pascoe biography
Richard W. Pascoe is Director of the Company. He has been a director since March 2013 and served as the Company’s Chief Executive Officer from March 2013 to December 2018, the Company’s Secretary from February 2015 to December 2018, and the Company’s Principal Financial Officer and Principal Accounting Officer from December 2016 to December 2018. He joined the Company following the merger of Somaxon Pharmaceuticals, Inc. with Pernix Therapeutics Holdings, Inc. Mr. Pascoe was the Chief Executive Officer of Somaxon from August 2008 until joining the Company and was responsible for the FDA approval of Somaxon’s lead drug Silenor®. Prior to Somaxon, Mr. Pascoe was with ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company where he was most recently Senior Vice President and Chief Operating Officer. Prior to joining ARIAD in 2005, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc. (acquired by Pfizer Inc.), including Senior Vice President positions in both marketing and sales, as well as Vice President positions in both international sales and marketing and hospital sales. Prior to King, Mr. Pascoe was in the commercial groups at Medco Research, Inc. (acquired by King), COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals Inc., the Takeda Oncology Company), B. Braun Interventional and The BOC Group. Mr. Pascoe is a member of the board of directors of KemPharm, Inc., as well as a member of the company’s audit and compensation committees and its lead independent director. He serves as a member of the board of directors of the Johnny Mac Soldiers Fund, a charity for military veterans. Mr. Pascoe is also a member of the board of directors of BIOCOM, as well as its Vice-President of Industry. Mr. Pascoe served as a Commissioned Officer with the U.S. Army 24th Infantry Division and continues to serve as a Civilian Aid to the Secretary of the Army. He is a graduate of the United States Military Academy at West Point where he received a B.S. degree in Leadership.
What is the salary of Richard Pascoe?
As the Director of Seelos Therapeutics, the total compensation of Richard Pascoe at Seelos Therapeutics is $917,292. There are no executives at Seelos Therapeutics getting paid more.
How old is Richard Pascoe?
Richard Pascoe is 55, he's been the Director of Seelos Therapeutics since 2019. There are 1 older and 2 younger executives at Seelos Therapeutics. The oldest executive at Seelos Therapeutics, Inc. is Dr. Raj Mehra J.D., Ph.D., 61, who is the Founder, Chairman, CEO & Pres.
What's Richard Pascoe's mailing address?
Richard's mailing address filed with the SEC is C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 2ND FLOOR, NEW YORK, NY, 10022.
Insiders trading at Seelos Therapeutics
Over the last 6 years, insiders at Seelos Therapeutics have traded over $0 worth of Seelos Therapeutics stock and bought 409,757 units worth $387,856 . The most active insiders traders include Brian Lian, Raj Mehra oraz Robin L Smith. On average, Seelos Therapeutics executives and independent directors trade stock every 231 days with the average trade being worth of $13,659. The most recent stock trade was executed by Raj Mehra on 1 December 2023, trading 75,757 units of SEEL stock currently worth $99,999.
What does Seelos Therapeutics do?
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
What does Seelos Therapeutics's logo look like?
Complete history of Mr. Pascoe stock trades at Zevra Therapeutics Inc i Seelos Therapeutics
Seelos Therapeutics executives and stock owners
Seelos Therapeutics executives and other stock owners filed with the SEC include:
-
Richard Pascoe,
Director -
Dr. Raj Mehra J.D., Ph.D.,
Founder, Chairman, CEO & Pres -
Daniel O'Connor,
Director -
Brian Lian,
Director -
Judith Dunn,
Director -
Warren Wasiewski,
Chief Scientific Officer -
Raj Mehra,
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer -
Tim Whitaker M.D.,
Chief Medical Officer -
Gopal Krishna Ph.D.,
Head of Manufacturing & Technical Operations -
Anthony Marciano,
Chief Communications Officer -
Kimberly Farrand,
Sr. Director of Clinical Devel. & Operations -
Michael J. Golembiewski,
Chief Financial Officer -
Robin L Smith,
Director -
Michael Joseph Golembiewski,
Chief Financial Officer